Accelerating the future of protein therapeutics
AI-driven protein design using our proprietary methods is accelerating biologics development — from antibodies to enzyme replacement therapies. Arzeda partners with industry leaders on protein-therapeutic optimization programs, including Takeda.
The Challenge
What our customers are facing
Bringing a protein therapeutic from target to patient is slow, expensive, and high-risk. Traditional methods burn months or years screening vast libraries of variants in the hope of finding a candidate that works — and even the proteins that win the screen often fail when they hit clinical-grade manufacturing or formulation.
Our Approach
How Arzeda delivers
Arzeda’s Intelligent Protein Design Technology™ designs and optimizes protein therapeutics for the properties that actually matter — efficacy, stability, manufacturability, and tolerability. Physics-based AI models trained on 15+ years of our own design-build-test data accelerates the path to success.
Related News
In March 2023, Arzeda announced a collaboration with Takeda to apply Arzeda’s Intelligent Protein Design Technology™ to optimize protein biologics in Takeda’s research pipeline. The collaboration uses computational design and machine learning to accelerate the optimization of proteins that can be incorporated into therapeutic products, addressing the kinds of design challenges that have historically slowed biologics development.
Partner with us
Join us as a partner
We will get back within 2 to 3 business days.